A retrospective study of 670 papillary thyroid carcinoma patients validates the 2025 ATA risk stratification system, demonstrating a shift toward higher-risk classifications. The new 'low-intermediate-risk' class emerges as a distinct entity with intermediate structural disease persistence risk, warranting dedicated prospective management studies.